Horizon Pharma plc and Hyperion Therapeutics, Inc. announced they have entered into a definitive agreement under which Horizon Pharma will...
Acer Therapeutics Inc. and its collaboration partner, Relief Therapeutics Holding SA announced that the FDA has approved Olpruva (sodium phenylbutyrate) for oral suspension in the U.S. for the treatment of certain patients living with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS)